Population aging, and the growing problem of antibiotic resistant pneumococci make these problems of increasing public health importance. 3 The current 23-valent pneumococcal vaccine covers 96% of all serious infections, 3 and is recommended for patients with chronic pulmonary disease, heart disease, renal disease, liver disease, immunodeficiency and immunosuppression, asplenia and severe splenic dysfunction, and diabetes. 4 However, uptake is believed to be low, with one recent survey suggesting that only 4% of those at risk had been covered. 5 We conducted a study of hospitalised patients with definite indications for pneumococcal vaccine to identify factors involved in the receipt or non-receipt of vaccine.
Subjects, methods and results
We surveyed patients admitted as medical emergencies (any cause) to the Emergency Admissions Unit of the Queen Elizabeth Hospital, a large teaching hospital in Birmingham, United Kingdom, prospectively between 2 April and 30 May 1998. Case records were used to identify patients with one or more chronic illnesses for which pneumococcal vaccine was currently recommended. A structured interview was then used to gather data on pneumococcal vaccine uptake (where given, by whom, and the reasons for receipt and non-receipt); details of recent health service contacts were also recorded. The interview schedule was piloted on 21 patients admitted as medical emergencies (any cause) to the same unit between 2 and 4 January 1998, after which minor amendments were made. During each interview, care was taken to avoid any possible confusion between pneumococcal and influenza vaccination. During the pilot study, patients' self reported vaccination histories were validated by telephone calls to general practitioners, and shown to be in complete agreement.
Analyses were performed using SPSS version 6.1.3. From a total of 466 consecutive patients, 384 case records (83%) were successfully screened; the remaining 82 records were missed because the patient was transferred to another hospital (n=15), discharged (n=55) or died (n=12) before screening could take place. Of 384 screened patients, 260 (68%) had indications for pneumococcal vaccine. Of these, 233 (90%) agreed to participate in the study.
Participants ranged from 21 to 97 years of age (19-44 = 28 (12%); 45-64 = 66 (28%); 65-74 = 53 (22%); 75-84 = 66 (28%); >85 = 20 (9%)), 106 (46%) were male, 39 (17%) non-white, 40 (17%) current smokers, and 100 (43%) previous smokers. Their indications for vaccine included chronic heart disease (n = 116 (50%)), chronic pulmonary disease (n = 110 (47%)), diabetes (n = 36 (15%)), chronic renal disease (n = 23 (10%)), immunodeficiency or immunosuppression (n = 9 (4%)), chronic liver disease (n = 8 (3%)) and asplenia or severe splenic dysfunction (n = 7 (3%)); 64 (27%) had more than one indication for vaccine. Their main reasons for hospital admission during April/May 1998 were pulmonary disease (n= 102 (44%)), cardiac disease (n = 87 (37%)), renal disease (n = 21 (9%)), diabetic emergencies (n = 8 (3%)), hepatic disease (n = 7 (3%)), haematological emergencies (n = 3 (1%)), malignancy (n = 3 (1%)), and anaemia with bleeding (n = 2 (1%)).
Of the 233 participants, 34 (15%) had been vaccinated; two more (1%) were unsure of their vaccination status. Two hundred and thirty subjects oVered reasons for receipt or non-receipt of vaccine (table 1) . Among recipients, the vast majority (85%) had done so because of advice received from their general practitioner. In comparison, less than 10% of patients had received advice from hospital staV. Similarly, general practitioners and practice nurses administered almost 95% of vaccine. The main reasons stated for nonreceipt of the vaccine were lack of awareness that it existed (77%) or failure to receive a recommendation from the general practitioner (15%). Four patients had previously suVered an adverse reaction to influenza vaccine and were afraid of a similar response to pneumococcal vaccine; the vaccine was contraindicated for three others because of current chemotherapy or radiotherapy. Of 233 patients, 229 (98%) had been hospitalised and 156 (67%) had attended a hospital outpatient clinic, at least once in the past five years (or since the onset of their vaccine defining illness if < 5 years). Only two persons (1%) had not attended their general practitioner in the past 12 months.
Comment
Although based on a series of hospitalised patients, virtually every unvaccinated person in this study represented a missed opportunity to deliver pneumococcal vaccine. This oVers 57-87% protection against invasive disease (bacteraemia or meningitis) even though its eVectiveness in high risk patients against pneumonia (in the absence of bacteraemia) is less firmly established. 6 Vaccine uptake was 15%, representing a level of coverage similar to that seen for influenza vaccine in the United Kingdom in the late 1980s. This finding is consistent with the amount of pneumococcal vaccine currently distributed in the United Kingdom compared with other developed countries especially the USA. 7 However, unlike annual influenza vaccination, pneumococcal vaccine may be given opportunistically at any time of year. The patients in this study had come into contact with health care workers on many previous occasions, presenting opportunities to oVer vaccine; however it is clear that many of these were missed and only one patient actually refused vaccine when oVered it. As with influenza vaccination, our data highlight the pivotal influence of an oVer from a member of the primary health care team, in determining whether pneumococcal vaccination takes place. Proactive management of pneumococcal vaccination in primary care settings could therefore help improve uptake. However, it is also clear that a large proportion of hospitalised patients could be opportunistically vaccinated against pneumococcal disease if this issue was considered before discharge.
